Clinical trial
Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis…
NCT00109304 · DynPort Vaccine Company LLC, A GDIT Company, Industry · Withdrawn
Key facts
| NCT number | NCT00109304 |
|---|---|
| Title | Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine |
| Official title | Safety, Tolerability and Immunogenicity of the Venezuelan Equine Encephalitis (VEE) Attenuated Live-Virus Vaccine VEE IA/B V3526 in VEE-Naive Healthy Volunteers After Single Dose Subcutaneous Administration |
| Lead sponsor | DynPort Vaccine Company LLC, A GDIT Company, Industry |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Venezuelan Equine Encephalitis |
| Intervention type | Biological |
| Interventions | VEE 3526 |
| Enrollment | 0 |
| Start date | Jul 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Apr 27, 2005 |
| Last update posted | Sep 18, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: